Erratum to: Update of Conservative Systemic Treatment of Uterine Fibroids

被引:0
|
作者
Magdalena Maria Zalewski
Felix Zeppernick
Joseph Neulen
机构
[1] Uniklinik RWTH Aachen,Klinik für Gynäkologie und Geburtsmedizin
[2] Johns Hopkins University School of Medicine,Department of Pathology
[3] Uniklinik RWTH Aachen,Klinik für Gynäkologische Endokrinologie und Reproduktionsmedizin
关键词
Uterine fibroids; Progesterone; Combined oral contraceptives; Levonorgestrel-releasing intrauterine systems; Gonadotropin-releasing hormone agonists; Ulipristal acetate;
D O I
10.1007/s13669-014-0093-8
中图分类号
学科分类号
摘要
Abstract Uterine fibroids are a common disease in women and lead to different symptoms, like pain and bleeding disorders. Apart from surgical treatment, there are many medical treatment options, which are presented in this article. Combined oral contraceptives and Levonorgestrel-releasing intrauterine systems are possible options for bleeding disorders that are a consequence of uterine fibroids. Gonadotropin-releasing hormone agonists and the new selective progesterone receptor modulator ulipristal acetate can effectively reduce myoma mass and vaginal bleeding rate. Ulipristal acetate should especially be considered for treatment in symptomatic women, as it has only a few noteworthy side effects.
引用
收藏
页码:196 / 200
页数:4
相关论文
共 50 条
  • [21] RETRACTED: Meta-Study of the Clinical Effect of Conservative Treatment in Uterine Fibroids (Retracted Article)
    Zhu, Hanxiao
    Lai, Xiaoli
    Wu, Jinhong
    Guan, Chenan
    Yu, Junhui
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [22] Experimental and new investigational drugs for the treatment of uterine fibroids
    Evangelisti, Giulio
    Ferrero, Simone
    Perrone, Umberto
    Gustavino, Claudio
    Volpi, Eugenio
    Izzotti, Alberto
    Barra, Fabio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (05) : 497 - 508
  • [23] Vilaprisan Progesterone receptor modulator Treatment of uterine fibroids
    Barra, F.
    Seca, M.
    Ferrero, S.
    DRUGS OF THE FUTURE, 2019, 44 (03) : 211 - 219
  • [24] Thermal ablative treatment of uterine fibroids
    Quinn, Stephen Derek
    Gedroyc, Wladyslaw M.
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2015, 31 (03) : 272 - 279
  • [25] ACR Appropriateness Criteria® Management of Uterine Fibroids: 2023 Update
    Makary, Mina S.
    Zane, Kylie
    Hwang, Gloria L.
    Kim, Charles Y.
    Ahmed, Osmanuddin
    Koepsel, Erica M. Knavel
    Monroe, Eric J.
    Scheidt, Matthew J.
    Smolock, Amanda R.
    Stewart, Elizabeth A.
    Wasnik, Ashish P.
    Pinchot, Jason W.
    JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2024, 21 (06) : S203 - S218
  • [26] Medical treatment of uterine fibroids. From the present to the future
    Goitia, M.
    Andres, M.
    Aquesolo, L.
    Azkuenaga, A.
    Cearsolo, A.
    de los Bueis, J.
    Diaz, T.
    Diez, S.
    Zilloniz, N. Martinez
    Millan, L.
    Silva, J.
    Urquijo, E.
    CLINICA E INVESTIGACION EN GINECOLOGIA Y OBSTETRICIA, 2023, 50 (02):
  • [27] The potential of selective progesterone receptor modulators for the treatment of uterine fibroids
    Bestel, Elke
    Donnez, Jacques
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (01) : 79 - 92
  • [28] Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids
    Tafi, Emanuela
    Scala, Carolina
    Maggiore, Umberto Leone Roberti
    Bizzarri, Nicolo
    Candiani, Massimo
    Venturini, Pier Luigi
    Ferrero, Simone
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 965 - 977
  • [29] Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
    Biglia, Nicoletta
    Carinelli, Silvestro
    Maiorana, Antonio
    D'Alonzo, Marta
    Lo Monte, Giuseppe
    Marci, Roberto
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 285 - 292
  • [30] Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids
    Ferrero, Simone
    Vellone, Valerio Gaetano
    Barra, Fabio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (01) : 107 - 116